Winterlight Labs and Genentech have announced new data showing the sensitivity of speech-based digital measures in detecting disease-related longitudinal change in Alzheimer’s disease.
Using data from Genentech’s Tauriel trial of semorinemab in early-stage Alzheimer’s disease (NCT03289143), these analyses provide new evidence that automated measures for assessing patient speech can characterize longitudinal decline with comparable sensitivity to clinician-administered neuropsychological assessments.
Read more about the analysis here.